Imugene (ASX:IMU) obtained fast track designation from the US Food and Drug Administration for azer-cel, a potential treatment for relapsed or refractory diffuse large B-cell lymphoma, according to a Wednesday filing with the Australian bourse.
Azer-cel is in phase 1b clinical trial, per the filing.
The designation will enable the clinical-stage immuno-oncology company to have more frequent meetings with the US FDA for development plans, the option for a rolling review of regulatory submissions, and potential eligibility for accelerated approval and priority review once relevant criteria are met, the filing stated.
The company's shares surged almost 6% in recent Wednesday trade.
Price (AUD): $0.04, Change: $+0.0020, Percent Change: +5.71%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.